SOURCE: BioDrain Medical, Inc.

BioDrain Medical, Inc.

July 28, 2011 08:00 ET

BioDrain Medical Enhances Intellectual Property Portfolio With Two Additional Patents Pending

Expands Coverage of Three Existing Registered Patents

MINNEAPOLIS, MN--(Marketwire - Jul 28, 2011) - BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, announced today two additional patents are pending for the Streamway System. This is in addition to the three issued patents for the Streamway System covering the United States, Europe, and Canada.

Chad Ruwe, Chief Operating Officer of BioDrain Medical Inc., said, "We continue to invest in our intellectual property portfolio and are pleased to see the steady progress of our filings for a Divisional Patent and a Continuation-In-Part Patent that are pending and under review by the United States Patent & Trademark Office."

Kevin Davidson, CEO of the Company, added, "The rapid acceptance of our system in hospitals heightens our awareness of the importance of having the highest possible level of patent protection. While our present patent portfolio is strong, these two additional steps expand our claims to cover recent enhancements to the system and also extend the effective protection of the original patents."

About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid management system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and the related germs, viruses and diseases that are potentially found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway system fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).

BioDrain's Streamway System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease-infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's Streamway system, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For more information, please visit www.biodrainmedical.com.

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Quarterly Report on Form 10-Q and related 8-K filings.

Contact Information

  • Investor Relations Contact:
    Stanley Wunderlich
    Consulting for Strategic Growth 1 Ltd.
    Tel: 800-625-2236 ext. 7770
    Email: Email Contact